| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocytes, Cardiac | 20 | 2023 | 183 | 3.260 |
Why?
|
| Myocardial Reperfusion Injury | 9 | 2021 | 51 | 2.890 |
Why?
|
| Glycogen | 8 | 2021 | 20 | 1.790 |
Why?
|
| Physical Conditioning, Animal | 5 | 2024 | 33 | 1.760 |
Why?
|
| Reperfusion Injury | 3 | 2023 | 58 | 1.400 |
Why?
|
| Heart | 7 | 2021 | 184 | 1.250 |
Why?
|
| Cell Death | 7 | 2023 | 278 | 1.230 |
Why?
|
| Myocardium | 16 | 2017 | 263 | 1.210 |
Why?
|
| Myocardial Infarction | 5 | 2022 | 247 | 1.090 |
Why?
|
| Physical Endurance | 2 | 2021 | 20 | 1.020 |
Why?
|
| Mice, Inbred C57BL | 10 | 2024 | 1869 | 0.990 |
Why?
|
| Iron | 3 | 2022 | 251 | 0.980 |
Why?
|
| Proto-Oncogene Proteins | 9 | 2005 | 257 | 0.930 |
Why?
|
| Weight Gain | 2 | 2024 | 139 | 0.900 |
Why?
|
| Cardiomegaly | 4 | 2011 | 44 | 0.890 |
Why?
|
| Corticosterone | 2 | 2024 | 90 | 0.860 |
Why?
|
| Body Temperature | 1 | 2024 | 35 | 0.850 |
Why?
|
| Animals | 48 | 2024 | 16992 | 0.840 |
Why?
|
| Heart Injuries | 1 | 2023 | 10 | 0.810 |
Why?
|
| Insulin | 5 | 2021 | 258 | 0.810 |
Why?
|
| Lactic Acid | 4 | 2021 | 112 | 0.780 |
Why?
|
| Brain | 3 | 2021 | 1472 | 0.770 |
Why?
|
| Signal Transduction | 16 | 2019 | 2157 | 0.760 |
Why?
|
| Blood Glucose | 4 | 2021 | 389 | 0.750 |
Why?
|
| Calcium Signaling | 3 | 2021 | 107 | 0.730 |
Why?
|
| Cell Survival | 7 | 2019 | 945 | 0.720 |
Why?
|
| Cardiovascular Diseases | 2 | 2019 | 749 | 0.710 |
Why?
|
| Ventricular Remodeling | 4 | 2022 | 61 | 0.710 |
Why?
|
| Heart Failure | 6 | 2022 | 302 | 0.680 |
Why?
|
| Hypoglycemia | 1 | 2021 | 24 | 0.670 |
Why?
|
| Mice | 25 | 2024 | 6644 | 0.640 |
Why?
|
| Polyketide Synthases | 2 | 2017 | 6 | 0.640 |
Why?
|
| Quinolones | 2 | 2017 | 14 | 0.620 |
Why?
|
| Apoptosis | 16 | 2022 | 1568 | 0.620 |
Why?
|
| Telomere-Binding Proteins | 1 | 2019 | 11 | 0.610 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 56 | 0.600 |
Why?
|
| Cell Division | 4 | 2007 | 311 | 0.580 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2019 | 760 | 0.560 |
Why?
|
| G2 Phase | 2 | 2007 | 28 | 0.540 |
Why?
|
| Osteosarcoma | 2 | 2007 | 30 | 0.530 |
Why?
|
| Evodia | 1 | 2017 | 2 | 0.530 |
Why?
|
| Bone Neoplasms | 2 | 2007 | 49 | 0.520 |
Why?
|
| Myocardial Ischemia | 5 | 2012 | 83 | 0.520 |
Why?
|
| Alkaloids | 1 | 2017 | 46 | 0.510 |
Why?
|
| Plants, Medicinal | 1 | 2017 | 57 | 0.500 |
Why?
|
| Mice, Transgenic | 9 | 2017 | 665 | 0.500 |
Why?
|
| Plant Proteins | 1 | 2017 | 102 | 0.490 |
Why?
|
| Proto-Oncogene Proteins c-akt | 10 | 2006 | 299 | 0.490 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 163 | 0.490 |
Why?
|
| Heart Diseases | 1 | 2017 | 112 | 0.480 |
Why?
|
| Adenoviridae | 9 | 2019 | 62 | 0.470 |
Why?
|
| Male | 27 | 2025 | 23409 | 0.450 |
Why?
|
| Rats | 19 | 2021 | 3735 | 0.430 |
Why?
|
| Guanosine Triphosphate | 1 | 2013 | 18 | 0.420 |
Why?
|
| Biomedical Research | 1 | 2019 | 502 | 0.420 |
Why?
|
| Hippocampus | 4 | 2019 | 594 | 0.400 |
Why?
|
| Gene Transfer Techniques | 3 | 2003 | 53 | 0.390 |
Why?
|
| Cytoskeletal Proteins | 1 | 2013 | 116 | 0.380 |
Why?
|
| Protein Multimerization | 1 | 2013 | 115 | 0.380 |
Why?
|
| Autoimmune Diseases | 2 | 2025 | 65 | 0.380 |
Why?
|
| Staphylococcus aureus | 1 | 2013 | 94 | 0.380 |
Why?
|
| Humans | 36 | 2025 | 43102 | 0.360 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2009 | 96 | 0.360 |
Why?
|
| Time Factors | 5 | 2021 | 1857 | 0.360 |
Why?
|
| Thiocyanates | 2 | 2010 | 7 | 0.350 |
Why?
|
| Rats, Wistar | 4 | 2021 | 283 | 0.350 |
Why?
|
| Phenylenediamines | 2 | 2023 | 10 | 0.340 |
Why?
|
| Cyclohexylamines | 2 | 2023 | 14 | 0.340 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2007 | 56 | 0.330 |
Why?
|
| Glucose | 2 | 2016 | 244 | 0.320 |
Why?
|
| Disease Models, Animal | 6 | 2021 | 1596 | 0.300 |
Why?
|
| Bacterial Proteins | 1 | 2013 | 595 | 0.290 |
Why?
|
| Indole Alkaloids | 1 | 2007 | 14 | 0.270 |
Why?
|
| Sp1 Transcription Factor | 2 | 2007 | 46 | 0.270 |
Why?
|
| Anticarcinogenic Agents | 1 | 2007 | 77 | 0.260 |
Why?
|
| Quinolines | 1 | 2007 | 78 | 0.260 |
Why?
|
| Cells, Cultured | 11 | 2017 | 1621 | 0.260 |
Why?
|
| Gene Targeting | 2 | 2005 | 39 | 0.250 |
Why?
|
| Muscle, Skeletal | 5 | 2021 | 316 | 0.250 |
Why?
|
| Obesity | 1 | 2015 | 1151 | 0.250 |
Why?
|
| Necrosis | 4 | 2015 | 54 | 0.240 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 134 | 0.240 |
Why?
|
| Blotting, Western | 6 | 2016 | 883 | 0.230 |
Why?
|
| Antibodies, Bispecific | 1 | 2025 | 5 | 0.230 |
Why?
|
| Antigen-Antibody Complex | 1 | 2025 | 20 | 0.230 |
Why?
|
| Transfection | 5 | 2019 | 532 | 0.230 |
Why?
|
| Lipid Peroxidation | 2 | 2022 | 140 | 0.220 |
Why?
|
| Thermogenesis | 1 | 2024 | 26 | 0.210 |
Why?
|
| Transgenes | 2 | 2015 | 65 | 0.210 |
Why?
|
| Liver | 2 | 2021 | 511 | 0.200 |
Why?
|
| Cicatrix | 1 | 2023 | 17 | 0.200 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 146 | 0.200 |
Why?
|
| Nuclear Proteins | 3 | 2004 | 333 | 0.200 |
Why?
|
| DNA, Viral | 1 | 2025 | 311 | 0.200 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2022 | 1 | 0.200 |
Why?
|
| Mice, Knockout | 5 | 2021 | 1035 | 0.190 |
Why?
|
| Porifera | 1 | 2022 | 16 | 0.190 |
Why?
|
| Cardiomyopathies | 1 | 2003 | 65 | 0.180 |
Why?
|
| Promoter Regions, Genetic | 4 | 2007 | 526 | 0.180 |
Why?
|
| Cell Line | 4 | 2019 | 1410 | 0.180 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2012 | 587 | 0.180 |
Why?
|
| Crystallography, X-Ray | 3 | 2017 | 280 | 0.170 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 2021 | 7 | 0.170 |
Why?
|
| Pulmonary Alveolar Proteinosis | 1 | 2021 | 1 | 0.170 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 14 | 0.170 |
Why?
|
| Gene Amplification | 1 | 2021 | 23 | 0.170 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2019 | 200 | 0.160 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 561 | 0.160 |
Why?
|
| Cyclic AMP | 1 | 2021 | 127 | 0.160 |
Why?
|
| Fibrosis | 2 | 2012 | 169 | 0.160 |
Why?
|
| Autoantibodies | 1 | 2021 | 117 | 0.160 |
Why?
|
| Gene Silencing | 2 | 2019 | 154 | 0.150 |
Why?
|
| Hydrogen Peroxide | 2 | 2019 | 190 | 0.150 |
Why?
|
| Perfusion | 2 | 2012 | 38 | 0.150 |
Why?
|
| Antioxidants | 2 | 2022 | 443 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 133 | 0.150 |
Why?
|
| Enzyme Activation | 4 | 2005 | 462 | 0.150 |
Why?
|
| Ubiquitin | 1 | 2019 | 81 | 0.140 |
Why?
|
| Ligation | 2 | 2012 | 12 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 307 | 0.140 |
Why?
|
| Annexin A5 | 2 | 2009 | 27 | 0.140 |
Why?
|
| Carbolines | 1 | 2017 | 17 | 0.140 |
Why?
|
| Reactive Oxygen Species | 3 | 2017 | 532 | 0.140 |
Why?
|
| Astrocytes | 2 | 2016 | 244 | 0.140 |
Why?
|
| Hemorrhage | 1 | 2018 | 55 | 0.130 |
Why?
|
| Mutation | 3 | 2021 | 1177 | 0.130 |
Why?
|
| Transcription, Genetic | 3 | 2007 | 592 | 0.130 |
Why?
|
| Coronary Vessels | 2 | 2012 | 92 | 0.130 |
Why?
|
| Ferric Compounds | 1 | 2017 | 62 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 734 | 0.130 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2016 | 12 | 0.130 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 704 | 0.130 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 1081 | 0.130 |
Why?
|
| Contrast Media | 2 | 2009 | 103 | 0.130 |
Why?
|
| Piperazines | 1 | 2017 | 120 | 0.130 |
Why?
|
| Mutagenesis | 2 | 2013 | 91 | 0.130 |
Why?
|
| Colonic Neoplasms | 2 | 2010 | 223 | 0.120 |
Why?
|
| Protein Structure, Tertiary | 2 | 2015 | 423 | 0.120 |
Why?
|
| Radiology | 1 | 2016 | 12 | 0.120 |
Why?
|
| Tissue Fixation | 1 | 2016 | 19 | 0.120 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2016 | 17 | 0.120 |
Why?
|
| Symporters | 2 | 2006 | 15 | 0.120 |
Why?
|
| Anatomy | 1 | 2016 | 25 | 0.120 |
Why?
|
| Inflammation | 2 | 2012 | 758 | 0.120 |
Why?
|
| Genetic Vectors | 6 | 2015 | 165 | 0.120 |
Why?
|
| RNA, Messenger | 5 | 2010 | 1271 | 0.120 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2011 | 166 | 0.120 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2016 | 81 | 0.120 |
Why?
|
| Ventricular Pressure | 1 | 2015 | 8 | 0.120 |
Why?
|
| DNA | 2 | 2012 | 592 | 0.110 |
Why?
|
| Memory | 1 | 2016 | 174 | 0.110 |
Why?
|
| Insulin Resistance | 2 | 2015 | 201 | 0.110 |
Why?
|
| Gram-Negative Bacteria | 1 | 2015 | 29 | 0.110 |
Why?
|
| Aspergillus oryzae | 1 | 2015 | 1 | 0.110 |
Why?
|
| Myocardial Contraction | 1 | 2015 | 46 | 0.110 |
Why?
|
| Glucose Intolerance | 1 | 2015 | 40 | 0.110 |
Why?
|
| Urinary Tract Infections | 1 | 2015 | 44 | 0.110 |
Why?
|
| Neurogenesis | 1 | 2015 | 63 | 0.110 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2015 | 34 | 0.110 |
Why?
|
| Cerebral Cortex | 1 | 2016 | 306 | 0.110 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 30 | 0.110 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 67 | 0.110 |
Why?
|
| Ventricular Function, Left | 1 | 2015 | 114 | 0.110 |
Why?
|
| Fungal Proteins | 1 | 2015 | 142 | 0.110 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2005 | 29 | 0.110 |
Why?
|
| Enterococcus faecalis | 1 | 2015 | 53 | 0.100 |
Why?
|
| Hypertrophy | 2 | 2005 | 34 | 0.100 |
Why?
|
| Protein Structure, Quaternary | 1 | 2013 | 69 | 0.100 |
Why?
|
| Acridones | 1 | 2013 | 1 | 0.100 |
Why?
|
| Hydrolysis | 1 | 2013 | 97 | 0.100 |
Why?
|
| Population Surveillance | 1 | 2015 | 246 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 140 | 0.100 |
Why?
|
| Acyltransferases | 1 | 2013 | 22 | 0.100 |
Why?
|
| Osteopontin | 1 | 2013 | 46 | 0.100 |
Why?
|
| Receptors, IgE | 2 | 2003 | 22 | 0.100 |
Why?
|
| Protein Structure, Secondary | 1 | 2013 | 182 | 0.100 |
Why?
|
| Trans-Activators | 2 | 2005 | 192 | 0.100 |
Why?
|
| Female | 11 | 2025 | 24698 | 0.100 |
Why?
|
| Middle Aged | 7 | 2025 | 12222 | 0.100 |
Why?
|
| Mast Cells | 2 | 2003 | 82 | 0.100 |
Why?
|
| Exercise | 1 | 2019 | 692 | 0.090 |
Why?
|
| Protein Isoforms | 2 | 2021 | 139 | 0.090 |
Why?
|
| Citrate (si)-Synthase | 1 | 2011 | 10 | 0.090 |
Why?
|
| Glucose Transporter Type 1 | 2 | 2016 | 20 | 0.090 |
Why?
|
| Microwaves | 1 | 2011 | 29 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2012 | 135 | 0.090 |
Why?
|
| Sulfoxides | 2 | 2010 | 18 | 0.090 |
Why?
|
| Isothiocyanates | 2 | 2010 | 20 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 432 | 0.090 |
Why?
|
| Ventricular Myosins | 1 | 2011 | 1 | 0.090 |
Why?
|
| Luciferases | 2 | 2010 | 71 | 0.090 |
Why?
|
| Phosphorylation | 4 | 2010 | 986 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2010 | 652 | 0.090 |
Why?
|
| Myocarditis | 1 | 2011 | 24 | 0.080 |
Why?
|
| Exercise Test | 1 | 2011 | 74 | 0.080 |
Why?
|
| Autophagy | 1 | 2012 | 140 | 0.080 |
Why?
|
| In Situ Nick-End Labeling | 4 | 2009 | 138 | 0.080 |
Why?
|
| Autoimmunity | 1 | 2011 | 58 | 0.080 |
Why?
|
| Genome-Wide Association Study | 2 | 2025 | 423 | 0.080 |
Why?
|
| Gene Expression | 2 | 2021 | 701 | 0.080 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 75 | 0.080 |
Why?
|
| Monophenol Monooxygenase | 1 | 2010 | 14 | 0.080 |
Why?
|
| Skin Pigmentation | 1 | 2010 | 23 | 0.080 |
Why?
|
| Hydroxamic Acids | 1 | 2010 | 33 | 0.080 |
Why?
|
| Glucose Transporter Type 4 | 2 | 2009 | 14 | 0.080 |
Why?
|
| Prostaglandin D2 | 1 | 2010 | 26 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2010 | 105 | 0.080 |
Why?
|
| Plasmids | 2 | 2016 | 244 | 0.080 |
Why?
|
| Melanins | 1 | 2010 | 42 | 0.080 |
Why?
|
| Carbocyanines | 1 | 2009 | 14 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2010 | 165 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2010 | 46 | 0.080 |
Why?
|
| Diabetic Angiopathies | 1 | 2009 | 26 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 2 | 2010 | 694 | 0.080 |
Why?
|
| Risk Factors | 1 | 2018 | 3994 | 0.070 |
Why?
|
| Monocytes | 2 | 2002 | 277 | 0.070 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2009 | 43 | 0.070 |
Why?
|
| Models, Cardiovascular | 1 | 2009 | 98 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2011 | 279 | 0.070 |
Why?
|
| Iodine Radioisotopes | 2 | 2006 | 38 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 2 | 2007 | 508 | 0.070 |
Why?
|
| Heart Ventricles | 1 | 2009 | 123 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2006 | 1766 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2011 | 760 | 0.070 |
Why?
|
| Myosin Heavy Chains | 2 | 2011 | 18 | 0.070 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2007 | 54 | 0.070 |
Why?
|
| Japan | 2 | 2021 | 348 | 0.070 |
Why?
|
| Response Elements | 1 | 2007 | 55 | 0.070 |
Why?
|
| NAD | 1 | 2007 | 45 | 0.070 |
Why?
|
| Fasting | 1 | 2007 | 56 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 2 | 2006 | 216 | 0.070 |
Why?
|
| Rats, Inbred OLETF | 2 | 2016 | 5 | 0.060 |
Why?
|
| Models, Molecular | 2 | 2025 | 876 | 0.060 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2004 | 66 | 0.060 |
Why?
|
| Mitochondria | 2 | 2007 | 523 | 0.060 |
Why?
|
| Hexokinase | 1 | 2005 | 10 | 0.060 |
Why?
|
| Deoxyglucose | 1 | 2005 | 18 | 0.060 |
Why?
|
| Intracellular Membranes | 1 | 2005 | 36 | 0.060 |
Why?
|
| Neurons | 3 | 2019 | 1263 | 0.060 |
Why?
|
| Aged | 5 | 2021 | 8214 | 0.060 |
Why?
|
| Phenotype | 2 | 2013 | 780 | 0.060 |
Why?
|
| Echocardiography | 2 | 2006 | 167 | 0.060 |
Why?
|
| Cryoelectron Microscopy | 1 | 2025 | 50 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2007 | 220 | 0.060 |
Why?
|
| Herpesvirus 6, Human | 1 | 2025 | 5 | 0.060 |
Why?
|
| Genes, erbB-2 | 1 | 2004 | 6 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2003 | 213 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2010 | 1455 | 0.060 |
Why?
|
| DNA, Complementary | 2 | 2002 | 196 | 0.060 |
Why?
|
| Cell Hypoxia | 2 | 2007 | 60 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 291 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2002 | 137 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 934 | 0.060 |
Why?
|
| Immediate-Early Proteins | 1 | 2005 | 49 | 0.050 |
Why?
|
| Transcription Factors | 3 | 2005 | 735 | 0.050 |
Why?
|
| Protein Subunits | 1 | 2004 | 93 | 0.050 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2004 | 1 | 0.050 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2004 | 2 | 0.050 |
Why?
|
| Mitochondria, Heart | 1 | 2004 | 60 | 0.050 |
Why?
|
| Sp3 Transcription Factor | 1 | 2004 | 8 | 0.050 |
Why?
|
| Body Weight | 2 | 2016 | 429 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2004 | 12 | 0.050 |
Why?
|
| Intracellular Fluid | 1 | 2003 | 26 | 0.050 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2005 | 70 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2004 | 29 | 0.050 |
Why?
|
| Calcium | 2 | 2003 | 491 | 0.050 |
Why?
|
| Cytokines | 1 | 2007 | 678 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2005 | 403 | 0.050 |
Why?
|
| Adult | 4 | 2025 | 13872 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2004 | 168 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2004 | 173 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2004 | 88 | 0.050 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2025 | 203 | 0.050 |
Why?
|
| Thrombopoietin | 1 | 2022 | 3 | 0.050 |
Why?
|
| Lectins | 1 | 2022 | 19 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 306 | 0.050 |
Why?
|
| Leukotriene C4 | 1 | 2002 | 6 | 0.050 |
Why?
|
| Hela Cells | 1 | 2004 | 376 | 0.050 |
Why?
|
| Phosphoproteins | 4 | 2005 | 206 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 2015 | 506 | 0.050 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2002 | 9 | 0.050 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2002 | 41 | 0.050 |
Why?
|
| Regional Blood Flow | 1 | 2002 | 53 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 197 | 0.040 |
Why?
|
| Drug Administration Routes | 1 | 2001 | 14 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 2853 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2021 | 20 | 0.040 |
Why?
|
| Cell Count | 1 | 2001 | 145 | 0.040 |
Why?
|
| Phenylephrine | 3 | 2006 | 34 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2003 | 228 | 0.040 |
Why?
|
| Pulmonary Surfactants | 1 | 2021 | 33 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2021 | 206 | 0.040 |
Why?
|
| Mice, Inbred NOD | 2 | 2011 | 51 | 0.040 |
Why?
|
| Proteins | 1 | 2003 | 382 | 0.040 |
Why?
|
| Risk | 1 | 2021 | 287 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2002 | 263 | 0.040 |
Why?
|
| Survival Rate | 1 | 2021 | 355 | 0.040 |
Why?
|
| Alleles | 1 | 2021 | 352 | 0.040 |
Why?
|
| Morpholines | 1 | 1999 | 72 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 159 | 0.040 |
Why?
|
| Chromones | 1 | 1999 | 53 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 587 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2003 | 403 | 0.040 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1999 | 113 | 0.040 |
Why?
|
| Cell Line, Tumor | 3 | 2015 | 2676 | 0.040 |
Why?
|
| Up-Regulation | 3 | 2007 | 536 | 0.040 |
Why?
|
| Exercise Therapy | 1 | 2019 | 87 | 0.030 |
Why?
|
| Prognosis | 1 | 2021 | 861 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 1067 | 0.030 |
Why?
|
| bcl-X Protein | 2 | 2010 | 27 | 0.030 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2009 | 23 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 458 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1285 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2003 | 512 | 0.030 |
Why?
|
| Carrier Proteins | 3 | 2003 | 321 | 0.030 |
Why?
|
| Gene Expression Regulation | 3 | 2010 | 1070 | 0.030 |
Why?
|
| RNA, Small Interfering | 2 | 2010 | 436 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 1600 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2003 | 384 | 0.030 |
Why?
|
| Immunoassay | 1 | 2016 | 74 | 0.030 |
Why?
|
| Radionuclide Imaging | 2 | 2006 | 29 | 0.030 |
Why?
|
| Biological Transport | 1 | 2016 | 204 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 93 | 0.030 |
Why?
|
| Klebsiella oxytoca | 1 | 2015 | 1 | 0.030 |
Why?
|
| Imipenem | 1 | 2015 | 3 | 0.030 |
Why?
|
| Amikacin | 1 | 2015 | 3 | 0.030 |
Why?
|
| Proteus mirabilis | 1 | 2015 | 3 | 0.030 |
Why?
|
| Ampicillin | 1 | 2015 | 8 | 0.030 |
Why?
|
| Vancomycin | 1 | 2015 | 7 | 0.030 |
Why?
|
| Fluoroquinolones | 1 | 2015 | 9 | 0.030 |
Why?
|
| Ciprofloxacin | 1 | 2015 | 16 | 0.030 |
Why?
|
| Serratia marcescens | 1 | 2015 | 3 | 0.030 |
Why?
|
| Eating | 1 | 2016 | 167 | 0.030 |
Why?
|
| Klebsiella pneumoniae | 1 | 2015 | 26 | 0.030 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2015 | 36 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 455 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 495 | 0.030 |
Why?
|
| Adrenergic alpha-Agonists | 2 | 2006 | 32 | 0.030 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2016 | 131 | 0.030 |
Why?
|
| Granzymes | 1 | 2015 | 19 | 0.030 |
Why?
|
| Immunodominant Epitopes | 1 | 2015 | 29 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2015 | 76 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2015 | 32 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2015 | 63 | 0.030 |
Why?
|
| Immunization | 1 | 2015 | 94 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2015 | 135 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2015 | 91 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2015 | 245 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 74 | 0.030 |
Why?
|
| Myostatin | 2 | 2006 | 61 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2015 | 132 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 249 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2021 | 2544 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2015 | 172 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2015 | 269 | 0.030 |
Why?
|
| Citrus | 1 | 2013 | 14 | 0.030 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2013 | 30 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2015 | 184 | 0.030 |
Why?
|
| Stress, Mechanical | 2 | 2005 | 164 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2013 | 51 | 0.030 |
Why?
|
| Phospholipase C gamma | 2 | 2003 | 9 | 0.030 |
Why?
|
| Sequence Analysis, Protein | 1 | 2013 | 52 | 0.030 |
Why?
|
| Antibodies | 1 | 2013 | 144 | 0.020 |
Why?
|
| Type C Phospholipases | 2 | 2003 | 23 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2013 | 118 | 0.020 |
Why?
|
| Mesothelioma | 1 | 2015 | 148 | 0.020 |
Why?
|
| Animals, Newborn | 2 | 2004 | 352 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2013 | 272 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2013 | 314 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2015 | 460 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2003 | 139 | 0.020 |
Why?
|
| Kinetics | 1 | 2013 | 695 | 0.020 |
Why?
|
| HLA-DQ Antigens | 1 | 2011 | 6 | 0.020 |
Why?
|
| Cardiac Myosins | 1 | 2011 | 7 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2013 | 465 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 800 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2011 | 68 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 1180 | 0.020 |
Why?
|
| Thymus Gland | 1 | 2011 | 76 | 0.020 |
Why?
|
| Autoantigens | 1 | 2011 | 87 | 0.020 |
Why?
|
| DNA Primers | 1 | 2011 | 294 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 1542 | 0.020 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2010 | 10 | 0.020 |
Why?
|
| Transcription Factor CHOP | 1 | 2010 | 11 | 0.020 |
Why?
|
| Arbutin | 1 | 2010 | 1 | 0.020 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 10 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 2010 | 13 | 0.020 |
Why?
|
| Glucose Clamp Technique | 1 | 2009 | 7 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2009 | 10 | 0.020 |
Why?
|
| NF-kappa B | 2 | 2003 | 358 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 98 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2010 | 195 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 113 | 0.020 |
Why?
|
| Phylogeny | 1 | 2013 | 769 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 79 | 0.020 |
Why?
|
| Base Sequence | 1 | 2011 | 983 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2010 | 408 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2009 | 227 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2010 | 178 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2011 | 972 | 0.020 |
Why?
|
| Methyl Methanesulfonate | 1 | 2007 | 6 | 0.020 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2007 | 6 | 0.020 |
Why?
|
| Sirtuin 3 | 1 | 2007 | 6 | 0.020 |
Why?
|
| Sirtuins | 1 | 2007 | 14 | 0.020 |
Why?
|
| Food Deprivation | 1 | 2007 | 33 | 0.020 |
Why?
|
| Infant | 1 | 2011 | 1175 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2007 | 102 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2007 | 154 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 2006 | 22 | 0.020 |
Why?
|
| Mutagens | 1 | 2007 | 74 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2007 | 118 | 0.020 |
Why?
|
| RNA Interference | 1 | 2007 | 247 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2006 | 148 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2006 | 209 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2005 | 20 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2007 | 383 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2004 | 21 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 2004 | 29 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 2004 | 51 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2005 | 62 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2005 | 107 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 256 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2005 | 116 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2005 | 185 | 0.010 |
Why?
|
| Onium Compounds | 1 | 2003 | 3 | 0.010 |
Why?
|
| Respiratory Burst | 1 | 2003 | 5 | 0.010 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2003 | 12 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 152 | 0.010 |
Why?
|
| Phosphotyrosine | 1 | 2003 | 23 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 575 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 2005 | 143 | 0.010 |
Why?
|
| Nanotechnology | 1 | 2005 | 176 | 0.010 |
Why?
|
| I-kappa B Proteins | 1 | 2003 | 36 | 0.010 |
Why?
|
| Feedback, Physiological | 1 | 2003 | 32 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2003 | 87 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 611 | 0.010 |
Why?
|
| Autocrine Communication | 1 | 2003 | 12 | 0.010 |
Why?
|
| Comet Assay | 1 | 2003 | 77 | 0.010 |
Why?
|
| Endothelin-1 | 1 | 2003 | 57 | 0.010 |
Why?
|
| Paracrine Communication | 1 | 2003 | 18 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2003 | 64 | 0.010 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2003 | 28 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2003 | 21 | 0.010 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2003 | 35 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2003 | 210 | 0.010 |
Why?
|
| Leukemia, Basophilic, Acute | 1 | 2002 | 4 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2003 | 27 | 0.010 |
Why?
|
| Thapsigargin | 1 | 2002 | 7 | 0.010 |
Why?
|
| Silver Nitrate | 1 | 2002 | 5 | 0.010 |
Why?
|
| Cell Degranulation | 1 | 2002 | 10 | 0.010 |
Why?
|
| Enzyme Precursors | 1 | 2002 | 12 | 0.010 |
Why?
|
| Calcium Channels | 1 | 2003 | 73 | 0.010 |
Why?
|
| Potassium Channels | 1 | 2003 | 80 | 0.010 |
Why?
|
| Age of Onset | 1 | 2003 | 114 | 0.010 |
Why?
|
| ras Proteins | 1 | 2003 | 54 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2003 | 92 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2002 | 75 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2002 | 2 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2003 | 56 | 0.010 |
Why?
|
| src-Family Kinases | 1 | 2002 | 49 | 0.010 |
Why?
|
| RNA, Complementary | 1 | 2002 | 10 | 0.010 |
Why?
|
| Tyrosine | 1 | 2002 | 120 | 0.010 |
Why?
|
| E-Selectin | 1 | 2002 | 23 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2002 | 168 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2003 | 411 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2002 | 32 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2002 | 59 | 0.010 |
Why?
|
| Silver | 1 | 2002 | 61 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2002 | 181 | 0.010 |
Why?
|
| I-kappa B Kinase | 1 | 2002 | 51 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2002 | 171 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2002 | 310 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2003 | 386 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2002 | 238 | 0.010 |
Why?
|
| Temperature | 1 | 2002 | 313 | 0.010 |
Why?
|
| Chemokine CCL2 | 1 | 2001 | 95 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2003 | 561 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2003 | 968 | 0.010 |
Why?
|